Thus, we examined the frequency of an extended panel of cancer-relevant mutations that could potentially reduce the initial response to TKIs in a cohort of newly diagnosed, EGFR-mutated, advanced NSCLC of primarily ADC subtype. This evidence concerns the gene EGFR and cancer.